Your browser doesn't support javascript.
loading
A review of amphetamine extended release once-daily options for the management of attention-deficit hyperactivity disorder.
Abbas, Kendall; Barnhardt, Elizabeth W; Nash, Patricia L; Streng, Maria; Coury, Daniel L.
Afiliación
  • Abbas K; Division of Developmental-Behavioral Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA.
  • Barnhardt EW; Division of Developmental-Behavioral Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA.
  • Nash PL; Division of Developmental-Behavioral Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA.
  • Streng M; Division of Developmental-Behavioral Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA.
  • Coury DL; Division of Developmental-Behavioral Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA.
Expert Rev Neurother ; 24(4): 421-432, 2024 Apr.
Article en En | MEDLINE | ID: mdl-38391788
ABSTRACT

INTRODUCTION:

Amphetamine preparations are one of the two categories of stimulant medications approved for the treatment of attention deficit hyperactivity disorder (ADHD). Optimal treatment of ADHD aims to reduce core symptoms for as much of the waking hours as possible, leading to longer-acting delivery formats. In addition, the pediatric population commonly has difficulty swallowing pills and manufacturers have developed a variety of options to facilitate this concern. These include chewable tablets, capsules that may be sprinkled on soft food, liquids and transdermal patches. AREAS COVERED This article reviews the once-daily extended-release preparations currently available for amphetamine compounds, their pharmacodynamics, and common adverse effects. EXPERT OPINION There is an extensive evidence base supporting use of amphetamine preparations in the treatment of ADHD. Rapid onset of action and a favorable side effect profile make these widely used. The availability of once-daily extended-release chewable tablets, capsules that can be opened and sprinkled, and liquid formulations provides clinicians with multiple options to meet the specific needs of patients with difficulty swallowing whole pills.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Trastorno por Déficit de Atención con Hiperactividad / Estimulantes del Sistema Nervioso Central / Metilfenidato Límite: Child / Humans Idioma: En Revista: Expert Rev Neurother Asunto de la revista: NEUROLOGIA / TERAPEUTICA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Trastorno por Déficit de Atención con Hiperactividad / Estimulantes del Sistema Nervioso Central / Metilfenidato Límite: Child / Humans Idioma: En Revista: Expert Rev Neurother Asunto de la revista: NEUROLOGIA / TERAPEUTICA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos